Molina Healthcare (MOH)
(Delayed Data from NYSE)
$325.43 USD
-4.87 (-1.47%)
Updated Oct 10, 2024 04:00 PM ET
After-Market: $325.43 0.00 (0.00%) 6:18 PM ET
3-Hold of 5 3
A Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$325.43 USD
-4.87 (-1.47%)
Updated Oct 10, 2024 04:00 PM ET
After-Market: $325.43 0.00 (0.00%) 6:18 PM ET
3-Hold of 5 3
A Value F Growth D Momentum D VGM
Zacks News
UnitedHealth (UNH) Wins New Medicaid Contract in Nebraska
by Zacks Equity Research
UnitedHealth's (UNH) UnitedHealthcare boasts a network of 100 hospitals and more than 14,000 physicians and caregivers in Nebraska.
Zacks Industry Outlook Highlights UnitedHealth Group, Humana, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth Group, Humana, Centene and Molina Healthcare are part of Zacks Industry Outlook article.
Molina (MOH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Molina (MOH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Has Axonics (AXNX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and Molina (MOH) have performed compared to their sector so far this year.
4 HMO Stocks to Watch Despite Escalating Technology Expenses
by Debasmita Chatterjee
A growing customer base and numerous contract wins might drive the Medical-HMO industry. However, high expenses related to technology advancements and a shortage of nurses will dampen margins. Stocks like UNH, HUM, CNC and MOH will likely ride out the industry storms.
Centene (CNC) Wins Contract to Serve Texas' Foster Population
by Zacks Equity Research
Centene's (CNC) Texas subsidiary secures a contract to continue catering to the state's foster children and youth via its Medicaid plans.
Encompass Health (EHC) Opens New 50-Bed Hospital in Naples
by Zacks Equity Research
With the new facility in Naples, Encompass Health (EHC) now has 153 inpatient rehabilitation units in total.
Humana (HUM) Hikes Guidance: Here's Why It's a Good Sign
by Zacks Equity Research
Humana (HUM) shaking off the discrete COVID-19 headwind from its guidance is an important milestone for the Medical - HMOs space.
Are Investors Undervaluing Molina Healthcare (MOH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
HCA Healthcare (HCA) Invests in VitalConnect's Remote Monitoring
by Zacks Equity Research
HCA Healthcare's (HCA) investment is likely to advance technology in the medical space, helping patients as well as professionals.
Is Molina Healthcare (MOH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Molina (MOH) and DocGo Inc. (DCGO) have performed compared to their sector so far this year.
Here's How Much a $1000 Investment in Molina Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Molina Healthcare (MOH) to Get New Medicaid Contract in Iowa
by Zacks Equity Research
Molina Healthcare's (MOH) Iowa health plan is likely to commence on Jul 1 next year.
Cigna (CI) to Widen Access to Individual Health Plans in 2023
by Zacks Equity Research
Cigna (CI) unveils enhanced individual and family health plans for its customers to opt for in the 2023 Open Enrollment Period. CI will enter newer counties and states to offer better health outcomes.
Is Molina Healthcare (MOH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Centene (CNC) Wins Medi-Cal Contracts but Loses 3 Counties
by Zacks Equity Research
Centene (CNC) is likely to appeal the decision to avoid disruption in services and it has time until Sep 1, 2022, to do so.
QIAGEN's (QGEN) New Syndromic Test to Combat Monkeypox Spread
by Zacks Equity Research
QIAGEN (QGEN) joins the global fight against monkeypox with the launch of its novel QIAstat-Dx Viral Vesicular Panel RUO.
Teleflex (TFX) Hit by Urolift Volume Decline, Cost Pressure
by Zacks Equity Research
In the Americas, growth within the Surgical business of Teleflex (TFX) is offset by a decline in Interventional Urology.
Here's How Much You'd Have If You Invested $1000 in Molina a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Edwards Lifesciences (EW) Gets CE Mark for PASCAL Precision
by Zacks Equity Research
Edwards Lifesciences' (EW) PASCAL Precision system enables precise navigation and implant delivery during mitral and tricuspid regurgitation treatment.
Here's Why Investors Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) better-than-expected results and expanded Panther installed base.
IDEXX (IDXX) Suffers From Macro Headwinds, Cost Constraints
by Zacks Equity Research
The strengthening of the rate of exchange for the U.S. dollar relative to other currencies has a negative impact on IDEXX's (IDXX) revenues.
What's in the Cards for Medtronic (MDT) in Q1 Earnings?
by Zacks Equity Research
Going by the industry-wide macro trend, we expect Medtronic (MDT) to once again report an adverse effect related to the global supply chain issues in fiscal Q1.
Boston Scientific (BSX) Signs Obsidio-Acquisition Agreement
by Zacks Equity Research
Boston Scientific's (BSX) latest acquisition will add the FDA-approved GEM technology to its interventional oncology and embolization portfolio.